Imagine your child is finally walking again.
After years of watching their muscles fade.
After being told the disease was fatal and progressive.
Then one day, a government letter arrives.
The medicine that gave you those baby steps?
It's being swapped. For a cheaper version. One that's never been tested in humans for this disease.
That's the nightmare playing out right now in Kerala.
It's called risdiplam — an innovator molecule that quietly rewrites how the body splices a single gene.
Not a painkiller. Not a vitamin.
A precision SMN2 exon-splicing modifier that works at the genomic level.
Since July 2021, Kerala has been giving it free to 120+ children with Spinal Muscular Atrophy.
The results are staggering:
The innovator bottle? Around ₹5.2 lakh at market price.
Kerala's previous LDF government negotiated it down to under ₹1 lakh.
But last October, Indian pharma giant Natco won a patent battle and launched its own generic — Natsmart — at roughly ₹15,900 a bottle.
A 97% discount.
For a cash-strapped state trying to cover more children, the math is irresistible.
More patients. Same budget. Easy call, right?
Not so fast.
Here's what's missing from the generic, according to K. Razeena of CureSMA Foundation of India:
Yes, it has DCGI marketing approval.
Yes, the recent court verdicts cleared the patent path.
But as Razeena puts it — those rulings were about patents, not about whether the drug actually works the same way inside a child's nervous system.
In most diseases, if a new drug doesn't work, you switch back.
In SMA, you can't.
Motor neurons, once lost, don't grow back.
Even tiny variations in drug exposure can mean a child stops walking — permanently.
And here's the kicker: not a single Central government centre of excellence in India has adopted generic risdiplam for routine SMA care yet.
Kerala would be the first.
Do you expand a life-saving scheme to more kids today…
or wait for the human data that protects every kid already on it.
The parents aren't saying no to affordability.
They're saying — show us the science first.
Because in a disease this unforgiving, cheaper and safer must mean the same thing.
That's all for now!
